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Abstract 
Background: Data on the prevalence and predictors for the development of pacing-
dependency in patients with cardiovascular implantable electronic devices (CIEDs) are sparse. 
Methods: Pacing-dependency defined as an absence of intrinsic rhythm of  ≥ 30 bpm was 
determined in 802 consecutive patients with CIEDs who visited the documented pacemaker or 
implantable cardioverter-defibrillator outpatient clinic for routine follow-up.  
Results: A total of 131 (16%) patients were found to be pacing-dependent 67 ± 70 months after 
CIED implant. Multivariate analysis revealed a significant association between pacing-
dependency and the following clinical variables: second or third-degree atrioventricular (AV) 
block at implant (OR = 19.9; 95% CI: 10.9–38.5, p < 0.01), atrial fibrillation at implant (OR = 
2.15; 95% CI: 1.16–4.05, p = 0.02), left ventricular ejection fraction (LVEF) ≤ 30% (OR = 2.06; 
95% CI: 1.03–4.15, p = 0.04), brain natriuretic peptide (BNP) > 150 pg/mL (OR = 2.12; 95% CI: 
1.16–3.97, p = 0.02), chronic kidney disease (OR = 1.86; 95% CI: 1.08–3.26, p = 0.03), and 
during follow-up after implantation > 5 years (OR = 3.29; 95% CI: 1.96–5.64, p < 0.01). None of 
the remaining clinical variables including age, gender, diabetes mellitus, underlying heart 
disease, prior cardiac surgery or medication during follow-up including beta-blockers and 
amiodarone predicted pacing-dependency. 
Conclusions: Pacing-dependency is associated with second or third-degree AV-block at implant, 
atrial fibrillation before implant, low LVEF, elevated BNP, chronic kidney disease and during 
follow-up after implant. 
Key words: pacing-dependency, permanent pacemaker, implantable cardioverter-
defibrillator  
 
 
Introduction  
 Knowledge of pacing-dependency following implantation of cardiovascular implantable 
electronic devices (CIEDs) is very important in various clinical settings including elective 
generator change, potential electromagnetic interference and management of suspected lead or 
generator malfunction [1, 2]. Although several million permanent pacemakers and implantable 
cardioverter-defibrillators (ICDs) with bradycardia pacing capability have been implanted 60 
years after the first pacemaker implantation in 1958, few studies have investigated the prevalence 
of pacing dependency and clinical predictors for the development of pacing dependency [3–
17]. Thus, the aim herein was to determine prevalence and predictors of pacing dependency in a 
well-defined cohort of 802 patients with pacemakers or implantable cardioverter-defibrillators at 
the documented clinic. 
 
Methods 
Study population 
 After written informed consent had been obtained, pacing dependency was determined 
prospectively in 802 consecutive patients who came to the pacemaker and ICD outpatient clinic 
for routine follow-up between January 2018 and December 2018 and in whom a permanent 
pacemaker or ICD had been implanted for at least 6 months by this institution. Pacing 
dependency was defined as an absence of intrinsic rhythm ≥ 30 bpm after lowering the pacing 
rate to 30 bpm for at least 10 s or after transient inhibition of pacing therapy (Fig. 1). A high-
degree atrioventricular (AV) block at implant was defined as second degree AV block type 
Mobitz or third-degree AV block. Chronic kidney disease (CKD) of at least stage 3 was 
diagnosed in the presence of at least two estimated glomerular filtration rates (eGFR) using the 
Modification of Diet in Renal Disease formula below 60 mL/min per 1.73 m2 with an interval of 
at least 3 months. The study protocol was reviewed and approved by the ethics committee of the 
Philipps-University of Marburg.  
 
Statistical analysis 
 Results are expressed as mean ± standard deviation (SD) for continuous variables with 
normal distribution and median values with interquartile range (IQR) for continuous variables 
without normal distribution. Univariate comparisons of clinical characteristics between patients 
with and without pacing dependency were performed using the Student t-test or the Mann-
Whitney U test for continuous variables, categorical values were compared using χ2 and the 
Fisher exact tests, where appropriate. Logistic regression analysis was used to generate a 
multivariate model including all potential predictors of pacing dependency listed in Table 1 in 
order to investigate which factors showed independent effects on the risk of developing 
pacemaker dependency after adjustment for confounding by other factors including the 
presence or absence of ICD therapy as well as cardiac resynchronization therapy (CRT). All 
probability values reported are two-sided, and a probability value of p < 0.05 was considered 
to indicate statistical significance. R-software version 3.5.0 (www.R-project.org) was used for 
statistical analyses. 
 
Results 
Clinical characteristics 
 The clinical characteristics of 802 study patients are summarized in Table 1 and included 
563 (70%) patients with a permanent pacemaker and 239 (30%) patients with an ICD. Mean 
duration between device implant and follow-up visit was 67 ± 70 months with a minimum 
implant duration of 6 months. The majority of patients were male (65%). Mean age at device 
implant was 74 ± 13 years. Indication for pacemaker implantation was a high-degree AV block 
in 247 (31%) patients, sick sinus syndrome in 196 (24%) patients, carotid sinus syndrome in 2 
(0.2%) patients, and atrial fibrillation with bradycardia in 125 (16%) patients. CRT devices were 
implanted in 93 of 802 study patients (12%) including CRT pacemakers in 25 of 563 pacemaker 
patients (4%) and CRT defibrillators in 68 of 239 (28%) patients with an ICD. 
  
Prevalence and predictors of pacing dependency  
 A total of 131 of 802 study patients (16%) were found to be pacing dependent at follow-up 
67 ± 70 months after the device implant. Pacing dependency at follow-up was found 
significantly more often in patients with New York Heart Association (NYHA) heart failure 
class 3 or 4, elevated B-type natriuretic peptide (BNP) > 150 pg/mL, decreased left ventricular 
ejection fraction (LVEF) ≤ 30%, CKD, high degree AV block at implant, left bundle branch 
block on electrocardiogram at implant, and implant duration > 5 years (Table 1). Multivariate 
logistic regression analysis revealed a significant association between pacing dependency and the 
following 6 clinical variables: second or third-degree AV block at implant (odds ratio [OR] = 
19.9; 95% confidence interval [CI]: 10.9–38.5, p < 0.01), atrial fibrillation at implant (OR = 
2.15; 95% CI: 1.16–4.05, p = 0.02), LVEF ≤ 30% (OR = 2.06; 95% CI: 1.03–4.15, p = 0.04), 
BNP > 150 pg/mL (OR = 2.12; 95% CI: 1.16–3.97, p = 0.02), CKD (OR = 1.86; 95% CI = 1.08–
3.26, p = 0.03), and follow-up duration > 5 years (OR = 3.29; 95% CI: 1.96–5.64, p < 0.01) 
(Table 2). None of the remaining clinical variables including age, gender, body mass index, 
arterial hypertension, diabetes mellitus, underlying heart disease, prior cardiac surgery, 
transcatheter aortic valve replacement or medication during follow-up including beta-blockers 
and amiodarone predicted pacing dependency. 
 
Subgroup analysis of 563 patients with permanent pacemaker  
The results for the subgroup of 563 patients with permanent pacemaker without 
cardioverter defibrillator back-up are summarized in Table 3. Pacing dependency at follow-up 
was found significantly more often in patients with NYHA heart failure class 3 or 4, elevated 
BNP > 150 pg/mL, decreased LVEF ≤ 30%, CKD, second or third-degree AV block at implant, 
and implant duration > 5 years. 
 
Subgroup analysis of 239 patients with ICD  
The results for the subgroup of 239 patients with ICD are summarized in Table 4. 
Pacing dependency at follow-up was found significantly more often in patients with NYHA 
heart failure class 3 or 4, elevated BNP > 150 pg/mL, decreased LVEF ≤ 30%, CKD, non-
ischemic dilated cardiomyopathy, amiodarone therapy, and implant duration > 5 years. In 
addition, left bundle branch block at implant, which was treated with a CRT defibrillator in 68 
patients with ICD, was also associated with a higher prevalence of pacing dependency at follow-
up (Table 4). 
 
Discussion 
 The main finding of the present study is a 16% prevalence of pacing dependency at 67 
months mean follow-up, which was associated with second or third-degree AV-block at implant, 
atrial fibrillation before implant, low LVEF, elevated BNP, CKD and implant duration. Although 
it is generally accepted that pacing dependency means absence of a sufficient intrinsic rhythm 
resulting in bradycardia-related symptoms during inhibition of pacing, the definition of pacing 
dependency is still controversial [12–14]. Similar to previous studies [5–7, 10], the current study 
defined pacing dependency as absence of an intrinsic rhythm of at least 30 bpm during 
pacemaker inhibition or ventricular pacing at a rate of lower than 30 bpm, whereas other 
investigators used an upper rate cutoff for the intrinsic rhythm of 40 bpm [4, 8, 9, 11] or 50 bpm 
[3] to define pacing dependency. The observed prevalence of pacing dependency of 16% in the 
present study is similar to the prevalence of 22% in a relatively large Canadian Trial of 
Physiologic Pacing (CTOPP), in which a pacemaker dependency test was performed in 2244 
patients [4]. Of note, the prevalence of pacing dependency varies in the literature between 2% in 
the study of Lekalowski et al. [6] and 63% in the study of Merin et al. [8] as summarized in 
Table 5. The discrepancy between these studies may, in part, be explained by differences in 
study patients as well as different definitions used for pacing dependency. Whereas the current 
study enrolled consecutive patients who came for routine device follow-up visits at the 
pacemaker and ICD outpatient department, Nagatamo et al. [5] excluded patients with an 
intrinsic rate of < 30 bpm at implant which likely contributed to a low prevalence of pacing 
dependency of 4% in the study by Nagatamo et al. [5]. In contrast to the study by Nagatamo et 
al. [5] and the present study, Merin et al. [8] found a high prevalence of pacing dependency of 
63% during follow-up. This discrepancy is likely to be due to the fact that the majority of 
patients in the study of Merin et al. [8] received a permanent pacemaker for third degree AV 
block without sufficient ventricular escape rhythm following cardiac surgery [8]. 
 The most important predictor of pacing dependency during follow-up in the current study was 
the presence second degree AV block type Mobitz or third-degree AV block at the time of 
pacemaker implant. This is consistent with the findings of most previous studies in patients with 
and without cardiac surgery prior to pacemaker implant [3, 5–8, 15–17]. Several previous 
investigators also found an association between pacing dependency during follow-up and body 
mass index [7], age [11], male gender [11], and a history of coronary artery disease [16]. Whereas 
none of these variables predicted pacing dependency in the present study, a significant association 
was found between pacing dependency and heart failure severity as indexed by a low LVEF ≤ 
30% and an elevated BNP level. Furthermore, amiodarone use was associated with pacing 
dependency in the subgroup of patients with ICD in the current study. This is consistent with the 
results of Sood et al. [11], who also found a significant association between pacing dependency 
and amiodarone use in a large cohort of 1058 patients with ICD. The results of the present study 
support the hypothesis that patients with heart failure and high degree AV block at implant will 
probably be paced more frequently in the ventricle and may therefore benefit from physiological 
pacing [4]. Although chronic kidney disease is a generally accepted important comorbidity in 
patients with heart disease of any etiology with regard to overall survival, the association between 
CKD and pacing dependency has not been investigated in previous studies [2–17]. Multivariate 
analysis in the current study revealed a twofold risk for pacing dependency in patients with CKD 
compared to patients without CKD. 
 
Limitations of the study 
 There are several limitations of the present study. First, clinical patient data and implant data 
were collected retrospectively, although pacing dependency was determined prospectively 
between January 2018 and December 2018 at the documented pacemaker and ICD outpatient 
department. Secondly, pacing dependency was determined during a brief period of time at a single 
outpatient visit. It is well known that pacing dependency can occur transiently. Therefore, repeated 
pacing dependency tests and longer monitoring time may have revealed patients, in whom pacing 
dependency may have resolved or may have occurred at other times.  
 
Conclusions 
 In conclusion, pacing dependency after CIED implantation depends on the pacing indication 
and is much more common in patients with high-degree AV-block at implant compared to patients 
with sick sinus syndrome. In addition, pacing dependency is associated with more advanced heart 
failure, chronic kidney disease and follow-up duration after implant. Since pacing dependent 
patients who suffer from heart failure will need frequent ventricular pacing, physiological pacing 
should be considered in these patients. 
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Table 1. Clinical characteristics of 802 patients with and without pacing dependency. 
 All patients Pacing-dependency P  
Clinical variable N = 802 Yes (n = 
131) 
No (n = 
671) 
Age [years] 74 ± 13 75 ± 12 74 ± 13 0.23 
Male gender 521 (65%) 89 (68%) 432 (64%) 0.50 
Body mass index [kg/m2] 28 ± 12 28 ± 5 28 ± 13 0.86 
Arterial hypertension 622 (78%) 105 (80%) 517 (77%) 0.27 
Diabetes mellitus 143 (18%) 19 (15%) 124 (18%) 0.43 
Atrial fibrillation before implant  242 (30%) 38 (29%) 205 (31%) 0.78 
Left bundle branch block at implant 141 (18%) 25 (19%) 116 (17%) 0.62 
Chronic kidney disease 330 (41%) 70 (53%) 260 (39%) < 0.01 
Heart failure severity 
Left ventricular ejection fraction ≤ 30% 179 (22%) 41 (31%) 138 (21%) < 0.01 
NYHA functional class III or IV 320 (40%) 74 (56%) 246 (37%) < 0.01 
B-type natriuretic peptide >150 pg/mLa 408 (57%) 77 (71%) 331 (54%) < 0.01 
Underlying cardiac disease 
Coronary artery disease 313 (39%) 45 (34%) 268 (40%) 
0.07 
Nonischemic dilated cardiomyopathy 119 (15%) 26 (20%) 93 (14%) 
Hypertensive heart disease  180 (22%) 35 (31%) 145 (22%) 
Valvular heart disease 101 (13%) 17 (15%) 84 (13%) 
Other cardiac diseasesb 13 (2%) 4 (4%) 9 (1%) 
No structural heart disease 76 (9%) 4 (4%) 72 (11%) 
Previous cardiac surgery 
Aortocoronary bypass grafting 95 (12%) 17 (13%) 78 (12%) 0.77 
Surgical aortic valve replacement 29 (4%) 4 (3%) 25 (4%) 0.90 
Mitral valve reconstruction or replacement 15 (2%) 1 (1%) 14 (2%) 0.50 
Transcatheter aortic valve replacement 43 (5%) 9 (7%) 34 (5%) 0.53 
Cardiovascular implantable electronic device 
Antibradycardia pacemaker 563 (70%) 103 (79%) 460 (69%) 
0.02 
Implantable cardioverter-defibrillator 239 (30%) 28 (21%) 211 (31%) 
Cardiac resynchronization therapy device 93 (12%) 20 (15%) 73 (11%) 0.07 
Median amount of ventricular pacing 
(IQR) 
30% (1–99) 100% (99–
100) 
12% (1–
82) 
< 0.01 
Indication for CIED implantation 
Sick sinus syndrome 196 (24%) 12 (9%) 184  (27%) 
< 0.01 
Second or third-degree AV block 247 (31%) 95 (73%) 152 (23%) 
Atrial fibrillation with bradycardia 125 (16%) 14(11%) 111 (17%) 
Carotid sinus syndrome 2 (0.2%) 0 (0%) 2 (0.3%) 
Prophylacticc 232 (29%) 10 (7%) 222 (33%) 
Implant duration > 5 years 330 (41%) 74 (56%) 256 (38%) < 0.01 
Medication 
Beta-blockers 539 (67%) 85 (65%) 454 (68%) 0.14 
Amiodarone 44 (5%) 7 (5%) 37 (6%) 0.94 
Digitalis 68 (8%) 9 (7%) 59 (9%) 0.58 
ACEI  419 (52%) 77 (59%) 342 (51%) 0.12 
Angiotensin receptor blockers 171 (21%) 25 (19%) 146 (22%) 0.57 
Diuretics 549 (68%) 100 (76%) 449 (67%) 0.04 
Aldosterone antagonists 226 (28%) 28 (21%) 198 (30%) 0.07 
Angiotensin-neprilysin inhibitor 25 (3%) 1 (1%) 24 (4%) 0.16 
Plus-minus values are given as mean ± standard deviation; ACEI — angiotensin converting enzyme inhibitors; 
AV — atrioventricular; CIED — cardiovascular implantable electronic device; IQR — interquartile range; 
NYHA — New York Heart Association 
aB-type natriuretic peptide was available in only 702 of 802 patients (88%) 
bOther cardiac diseases include hypertrophic cardiomyopathy, cardiac sarcoidosis, cardiac amyloidosis, and 
tricuspid valve replacement 
cImplantable cardioverter-defibrillator without symptomatic bradyarrhythmia at implant 
 
 
Table 2. Results of the multivariate analysis for pacing dependency in 802 study patients 
Clinical variable OR (95% CI)a Pa 
Left ventricular ejection fraction ≤ 30% 2.06 (1.03–4.15) 0.04 
Brain natriuretic peptide >150 pg/mL 2.12 (1.16–3.97) 0.02 
Second- or third-degree AV block at implant 19.9 (10.9– 8.5) < 0.01 
Atrial fibrillation before implant 2.15 (1.16–4.05) 0.02 
Chronic kidney disease 1.86 (1.08–3.26) 0.03 
Implant duration > 5 years 3.29 (1.96–5.64) < 0.01 
AV — atrioventricular; CI — confidence intervals; OR — odds ratio 
aAfter adjustment for potential confounding clinical variables as summarized in Table 1 including medication, 
implantable cardioverter defibrillator therapy and cardiac resynchronization therapy 
 
 
Table 3. Subgroup analysis of 563 patients with permanent pacemaker. 
 All patients Pacemaker dependency P 
Clinical variable N = 563 Yes (n = 
103) 
No (n = 
460) 
Age [years] 76 ± 12 77 ± 12 76 ± 12 0.57 
Male gender 336 (60%) 68 (66%) 268 (58%) 0.18 
Atrial fibrillation before implant  194 (34%) 30 (29%) 164 (36%) 0.25 
Left bundle branch block at implant 71 (13%) 11 (11%) 60 (13%) 0.51 
Chronic kidney disease 230 (41%) 55 (53%) 175 (38%) < 0.01 
Heart failure severity 
Left ventricular ejection fraction ≤ 30% 60 (11%) 18 (17%) 42 (9%) 0.02 
NYHA functional class III or IV 195 (35%) 53 (51%) 142 (31%) < 0.01 
B-type natriuretic peptide >150 pg/mLa 264 (54%) 56 (68%) 208 (51%) < 0.01 
Underlying cardiac disease 
Coronary artery disease 201 (36%) 37 (37%) 164 (36%) 
0.05 
Nonischemic dilated cardiomyopathy 26 (5%) 8 (8%) 18 (4%) 
Hypertensive heart disease  169 (30%) 35 (34%) 134 (29%) 
Valvular heart disease 88 (16%) 16 (16%) 72 (16%) 
Other cardiac diseasesb 5 (1%) 3 (3%) 2 (0.4%) 
No structural heart disease 74 (13%) 4 (4%) 70 (15%) 
Previous cardiac surgery 
Aortocoronary bypass grafting 55 (10%) 11 (11%) 44 (10%) 0.87 
Surgical aortic valve replacement 20 (4%) 4 (4%) 16 (3%) 0.84 
Mitral valve reconstruction or replacement 12 (2%) 1 (1%) 11 (2%) 0.37 
Transcatheter aortic valve replacement 41 (7%) 8 (8%) 33 (7%) 0.83 
Indication for pacemaker implantation 
Sick sinus syndrome 190 (34%) 12 (12%) 178 (39%) 
< 0.01 
Second or third-degree AV block 227 (40%) 79 (77%) 148 (32%) 
Atrial fibrillation with bradycardia 119 (21%) 12 (12%) 107 (23%) 
Carotid sinus syndrome 2 (0.4%) 0 (0%) 2 (0.4%) 
Cardiac resynchronisationb 25 (4%) 0 (0%) 25 (5%) 
Implant duration > 5 years 222 (39%) 59 (57%) 163 (35%) < 0.01 
Medication 
Beta-blockers 331 (59%) 59 (57%) 272 (59%) 0.47 
Amiodarone 18 (3%) 0 (0%) 18 (4%) 0.08 
Digitalis 46 (8%) 5 (5%) 41 (9%) 0.25 
ACEI  278 (43%) 58 (56%) 220 (48%) 0.15 
Angiotensin receptor blockers 114 (20%) 18 (17%) 96  (21%) 0.52 
Diuretics 362 (64%) 73 (71%) 289 (63%) 0.12 
Aldosterone antagonists 89 (16%) 12 (12%) 77 (17%) 0.26 
Angiotensin-neprilysin inhibitor 9 (2%) 1 (1%) 8 (2%) 0.89 
Abbreviations as in Table 1.  
aB-type natriuretic peptide was available only in 467 of 539 patients (66%) 
bPatients with heart failure and left bundle branch block 
 
 
Table 4. Subgroup analysis of 239 patients with implantable cardioverter-defibrillator. 
 All patients Pacemaker dependency P 
Clinical variable N = 239 Yes (n = 
28) 
No (n = 
211) 
Age [years] 68 ± 12 68 ± 12 68 ± 12 0.93 
Male gender 185 (77%) 21 (75%) 164 (78%) 0.81 
Atrial fibrillation before implant  48 (20%) 8 (29%) 40 (19%) 0.41 
Left bundle branch block at implant 70 (29%) 14 (50%) 56 (25%) 0.02 
Chronic kidney disease 100 (42%) 15 (54%) 85 (40%) 0.18 
Heart failure severity 
Left ventricular ejection fraction ≤ 30% 119 (50%) 23 (82%) 96 (45%) < 0.01 
NYHA functional class III or IV 125 (52%) 21 (75%) 104 (49%) 0.01 
Brain natriuretic peptide >150 pg/mLa 144 (61%) 21 (78%) 123 (59%) < 0.01 
Underlying cardiac disease 
Coronary artery disease 112 (47%) 8 (29%) 104 (49%) 
0.03 
Nonischemic dilated cardiomyopathy 93 (39%) 18 (64%) 75 (36%) 
Hypertensive heart disease  11 (5%) 0 (0%) 11 (5%) 
Valvular heart disease 13 (5%) 1 (4%) 12 (6%) 
Other cardiac diseasesb 8 (3%) 1 (4%) 7 (3%) 
No structural heart disease 2 (1%) 0 (0%) 2 (1%) 
Previous cardiac surgery 
Aortocoronary bypass grafting 40 (17%) 6 (21%) 34 (16%) 0.66 
Surgical aortic valve replacement 9 (4%) 0 (0%) 9 (4%) 0.27 
Mitral valve reconstruction or replacement 3 (1%) 0 (0%) 3 (1%) 1.00 
Transcatheter aortic-valve replacement 2 (1%) 1 (4%) 1 (0.5%) 0.56 
Indication for antibradycardia pacing at ICD implant 
Sick sinus syndrome 6 (3%) 0 (0%) 6 (3%) 
<0.01 
Second or third-degree AV block 20 (8%) 16 (57%) 4 (2%) 
Atrial fibrillation with bradycardia 6 (3%) 2 (7%) 4 (2%) 
Cardiac resynchronization therapyb 68 (28%) 20 (71%) 48 (23%) 
Implant duration > 5 years 108 (45%) 15 (54%) 93 (44%) 0.03 
Medication, 
Beta-blockers 208 (87%) 26 (93%) 182 (86%) 0.49 
Amiodarone 26 (11%) 7 (25%) 19 (9%) 0.03 
Digitalis 22 (9%) 4 (14%) 18 (9%) 0.52 
ACEI  141 (59%) 19 (68%) 122 (58%) 0.31 
Angiotensin receptor blockers 57 (24%) 7 (25%) 50 (24%) 0.88 
Diuretics 187 (78%) 27 (96%) 160 (76%) 0.03 
Aldosterone antagonists 137 (57%) 16 (57%) 121 (57%) 0.98 
Angiotensin-neprilysin inhibitor 16 (7%) 0 (0%) 16 (8%) 0.27 
Abbreviations as in Table 1. 
aB-type natriuretic peptide was available in 235 of 239 patients (98%) 
bPatients with heart failure and left bundle branch block 
 
 
Table 5. Prevalence of pacing-dependency in studies with at least 50 patients. 
Author 
Yea
r 
Patient
s 
ICD 
Cardiac 
surgery 
Follow-up 
[months] 
Pacing-
dependen
cy 
Intrinsic 
rhythm 
[bpm]a 
Glikson et al. [3] 1997 86 0% 100% 41 (median) 51 (59%) < 50  
Tang et al. [4] 2001 2244 0% NA 2 to 8 484 (22%) < 40  
Nagatomo et al. [5] 2004 518 0% NA 44 ± 32 23 (4%) < 30  
Lelakowski et al. [6] 2007 3638 0% NA 58 ± 22 76 (2%) < 30  
Onalan et al. [7] 2008 102 0% 100% 48 (mean) 21 (23%) < 30  
Merin et al. [8] 2009 58 0% 100% 72 ± 32 37 (63%) < 40  
Raza et al. [9] 2011 90 0% 100% 67 ± 50 36 (40%) < 40  
Rene et al. [10] 2013 98 0% 100% 43 ± 41 44 (45%) < 30  
Sood et al. [11] 2013 1058 100% NA 50 ± 41 142 (13%) < 40b 
Present study 2019 802 30% 30% 67 ± 70 131 (16%) < 30  
NA — data not available 
aIntrinsic rhythm used to define pacemaker dependency 
bIntrinsic rhythm < 40 bpm or < 50 bpm with symptoms 
 
Figure 1. Electrocardiogram recordings with a paper speed of 25 mm/s showing typical 
examples of ventricular asystole following transient inhibition of pacing; A. Ventricular 
asystole due to third degree atrioventricular (AV) block without ventricular escape rhythm in a 
patient with permanent atrial fibrillation; B. Ventricular asystole due to sinus arrest without 
escape rhythm in a patient with sinus node disease; C. Ventricular asystole due to third degree 
AV block without ventricular escape rhythm in a patient with second degree AV block type 
Mobitz at the time of pacemaker implant. 
Figure 1A 
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